These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis.
    Author: Mou S, Wang Q, Li J, Shi B, Ni Z.
    Journal: Clin Chim Acta; 2012 Jan 18; 413(1-2):187-91. PubMed ID: 21958699.
    Abstract:
    BACKGROUND: To evaluate the value of basal urinary L-FABP (uL-FABP) excretion as a prognostic indicator of the progression of kidney function impairment in patients with chronic glomerulonephritis (CGN). METHODS: One hundred twenty-three patients with newly diagnosed, biopsy-proven primary CGN were included. In all patients, and in 28 healthy subjects, uL-FABP was measured using an ELISA. Risk factors of the progression of kidney function were evaluated. The patients were in follow-up for at least 5 years. RESULTS: uL-FABP in the patients with CGN (76.58±17.3 μg/g.cr) was greater than in the healthy subjects. A significant positive correlation between uL-FABP and proteinuria (R=0.501, P<0.01), serum creatinine (R=0.601, P<0.01) were found. Kaplan-Meier analysis revealed that uL-FABP >76.58 μg/g.cr predicts progression of renal function. The cut off values for L-FABP at 119.8 μg/g.cr was found to be more sensitive, area under the curve (AUC) was 0.95. CONCLUSION: Urinary L-FABP may be a useful clinical biomarker for monitoring chronic glomerular disease. Urinary L-FABP can help predict the progression of chronic glomerular disease.
    [Abstract] [Full Text] [Related] [New Search]